Triple and Quadruple Eradication Therapy for H. pylori in Iraqi Patients with Peptic Ulcer Disease a Comparative Study

Ali, Z. A. G. M.; Hummadi, Y. M. K. A. M.; Najeeb, Akram Ajeel

doi:10.9734/bjmmr/2015/15598

Cited by 3 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies were conducted to evaluate the most effective therapeutic regimen for improving the eradication rate of H. pylori infection and obtaining higher healing efficacy [17][18][19][20][21]. This study is another attempt in this respect, though at a smaller scale, which might be (at least to best knowledge) the first attempt to evaluate the efficacy of curcumin as an adjuvant to the standard triple H. pylori eradication therapy.…”

Section: Discussionmentioning

confidence: 99%

“…With reference to the global trend of H. pylori eradication therapy which has now shifted towards proton pump inhibitor (PPI)-based triple therapy (a PPI and different antimicrobials) [6], which was studied extensively on Iraqi group of patients as well [21,44] can assure rapid symptom relief, reduce ulcer recurrence, and improve ulcer healing. However, many bacterial and host factors are contribute to the failure of H. pylori eradication, especially factors affecting PPI bioavailability and metabolism [45,46], besides the low patient compliance, especially in elderly patients [47,48].…”

Section: Abbas Et Almentioning

confidence: 99%

See 1 more Smart Citation

Potential Benefit of Curcumin Adjuvant Therapy to the Standard H. Pylori Eradication Therapy in Patients With Peptic Ulcer Disease

Abdulridha¹,

Abbas

Najeb

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: This study was designed to explore the benefit of curcumin as adjuvant therapy to the standard Helicobacter pylori eradication triple therapy in both duodenal and gastric ulcers patients.Methods: The present study enrolled 40 patients newly diagnosed endoscopically with peptic ulcer disease to be allocated into group 1 treated with standard H. pylori eradication triple therapy, and group 2 patients treated with curcumin (500 mg) capsules three times daily for 14 days as an adjuvant to standard triple therapy. Stool antigen test, immunoglobulin M serology test, tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β), and total antioxidant capacity (T-AOC) are measured at the baseline and after 6 weeks of treatment. Results:The result showed that the use of curcumin as adjuvant therapy produced highly significant improvement in healing efficacy which was significantly distinguished in duodenal ulcer patients compared to gastric ulcer groups 2 patients (p<0.05), along with a highly significant reduction in pro-inflammatory IL-1β level in group 2 patients (p<0.01). After 6 weeks of treatment, there was a highly significant elevation in the level of TNF-α in groups 1 (p<0.01), though group 2 patients presented with non-significant elevation in TNF-α level. Moreover, the T-AOC was improved with curcumin adjuvant therapy, though non-significant, compared to group 1 patients who showed a reduction in T-AOC. Conclusion:This study revealed that addition of curcumin as adjuvant therapy produced improvement in ulcer healing efficacy, and controlled the inflammatory and oxidative stress process induced by H. pylori infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Abbas Et Almentioning

confidence: 99%

Potential Benefit of Curcumin Adjuvant Therapy to the Standard H. Pylori Eradication Therapy in Patients With Peptic Ulcer Disease

Abdulridha¹,

Abbas

Najeb

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…A very high resistance rates toward metronidazole have been reported, particularly in female patients in developing countries [88], which may be more likely due to the prior treatment with metronidazole for gynecological diseases [89].…”

Section: Ulcer Healing Efficacy Of Standard Triple and Quadruple H Pmentioning

confidence: 99%

Clinical Evaluation of Triple and Quadruple Helicobacter Pylori Eradication Therapy in Peptic Ulcer Patients With Different Abo Blood Group Phenotypes

Abdulridha

Kutaif

Kamal

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: This study aimed to examine the pathological changes in gastric mucosa of Helicobacter pylori-infected peptic ulcer patients carrying different ABO phenotypes and to study the response to the 14 days' standard triple therapy and 10 days' quadruple therapy in peptic ulcer patients according to their ABO phenotypes. Methods:Interventional prospective randomized-controlled open-label study was performed on newly diagnosed patients with PUD. The H. pyloripositive patients were allocated into two major study groups in which they are subdivided according to ABO blood group phenotypes: Group 1 received standard H. pylori eradication triple therapy and Group 2 received standard H. pylori eradication quadruple regimen. Patients were monitored after 2 months for successful H. pylori eradication.Results: Chronic active gastritis was significantly high in patients carrying blood Group O phenotype (81.25%), while the atrophic gastritis and intestinal metaplasia were significantly high in patients carrying blood Group A phenotype (25.00% and 16.67%), respectively. 14 days' triple therapy showed significantly lower eradication rate in H. pylori-infected peptic ulcer patients carrying blood Group O phenotype (p<0.01), meanwhile higher response was found among patients with blood Group B. 10 days' quadruple therapy produced a significant high eradication rate in H. pylori-infected patients carrying blood Group O than those with blood Group A (p<0.01), but still both showed lower response compared to that in patients carrying blood Group B and AB phenotypes. Elderly patients showed significantly less healing efficacy than younger patients (p<0.01), and the least healing rate was noticed in female patients after both regimens. Conclusion:Lower eradication rate in H. pylori-infected was noticed in peptic ulcer patients carrying blood Group O mainly than those with other blood groups and particularly those with duodenal Ulceri. 10 days' quadruple therapy showed significant higher eradication rate in H. pylori infection and a better ulcer healing efficacy.

show abstract

The Evaluation of Triple, Quadruple, and Levofloxacin-Based Therapy in the Management of Helicobacter Pylori Infection Among Dyspeptic Patients

Mohammed¹,

Arif²,

Mohammed³

2019

JSMC

View full text Add to dashboard Cite

Background The eradication rate for the first line therapy in H. pylori infection declined worldwide as a result of resistance development; however other therapies as quadruple and levofloxacin-based therapy are also used and have different eradication rate. Objectives To assess the response rate of H. pylori infection for different drug’s regimens (triple, quadruple, and levobased), and evaluate the effect of age, gender, body mass index and compliance of the patients on the regimens response rate. Methods A cross- sectional study, conducted in Kurdistan Center for Gastroenterology and Hepatology (KCGH) in Sulaimani, from April 2018 –November 2018. The study Included 753 dyspeptic patients, H. pylori were positive in 430 (57.1%) patients. Demographic data, anthropometric measures, and clinical presentations were recorded for the participants. The participants were randomly treated with one of the standard H. pylori eradication regimens (triple, quadruple or levobased), they have been followed up for 45 days and rechecked for H. pylori. Results The mean age of the patients was 39.8± 15.6 years, and the mean Body Mass Index was 25.7± 6.1kg/m2, 182(42.3%) were male and 248 (57.7%) were female. The rates of responses were (84.4%, 89.4%, and 97.4%) for the triple, quadruple and levobased regimens respectively. The most adverse effects were dizziness and metallic taste recorded in 30.3% in the quadruple group. Statistically, a significant difference was found in the response rate among the triple, quadruple and levobased regimens (p= 0.033). There were no significant differences in the response rate among the three regimens group regarding age, gender, and body mass index. More than 95% in those who completed follow up were adherent to their regimens. Conclusion Triple and quadruple regimens are still effective for H. pylori eradication, but have more adverse effects than levobased regimens. Levobased regimen has highest eradication rate for H. pylori, better compliance, and least adverse effects.

show abstract

Triple and Quadruple Eradication Therapy for H. pylori in Iraqi Patients with Peptic Ulcer Disease a Comparative Study

Cited by 3 publications

References 45 publications

Potential Benefit of Curcumin Adjuvant Therapy to the Standard H. Pylori Eradication Therapy in Patients With Peptic Ulcer Disease

Potential Benefit of Curcumin Adjuvant Therapy to the Standard H. Pylori Eradication Therapy in Patients With Peptic Ulcer Disease

Clinical Evaluation of Triple and Quadruple Helicobacter Pylori Eradication Therapy in Peptic Ulcer Patients With Different Abo Blood Group Phenotypes

The Evaluation of Triple, Quadruple, and Levofloxacin-Based Therapy in the Management of Helicobacter Pylori Infection Among Dyspeptic Patients

Contact Info

Product

Resources

About